Please assess the completion status of the following clinical trial:

Trial Title: Myocardial Protection of Exenatide in AMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 20 and 79 years~* patients presenting with first ST-segment elevation myocardial infarction~* Thrombolysis in Myocardial Infarction \[TIMI\] flow grade 0)~Exclusion Criteria:~* cardiac arrest~* ventricular fibrillation~* cardiogenic shock~* hemodynamic instability~* suspicious stent thrombosis~* left bundle branch block~* previous acute myocardial infarction~* previous coronary artery bypass operation~* significant valvular heart disease~* primary myocardial disease~* atrial fibrillation~* significant hepatic or renal dysfunction, hypoglycaemia,~* diabetic ketoacidosis~* active infection or chronic inflammatory disease~* malignancy~* women who were pregnant or who were of childbearing age

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: ACTIVE_COMPARATOR): Drug: Exenatide~10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days.
- Saline (Type: PLACEBO_COMPARATOR): Drug: Saline~10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).